Home » Newsletters » BioWorld Science

BioWorld Science

June 17, 2020

View Archived Issues

Lifespan synaptic atlas gives developmental insights

Prozac for infectious disease

Staten begins first-in-human study of STT-5058 for hypertriglyceridemia

Phase IIa data reported for Sym-015 in non-small cell lung cancer patients

KAND-567 demonstrates positive effect on mobility in a preclinical model of spinal cord injury

MK-1092 demonstrates safety and promising glucose-lowering activity

Phase Ib data for ningetinib and gefitinib in EGFR-TKI-resistant NSCLC

Positive data reported from phase II AFFIRM-35 study of ABY-035

First patient dosed in dose-expansion stage of phase Ib/II trial of cavrotolimod

Bisantrene phase II study in AML yields positive results

Pfizer describes new hemoglobin subunit beta polymerization inhibitors

New PCSK9 inhibitors discovered at Novartis

BioVersys synthesizes compounds interacting with accessory gene regulator A

Vyome releases positive phase II results for VB-1953

3M Pharmaceuticals patents cytokine biosynthesis inducers

Netakimab demonstrates superiority to placebo in second-line psoriatic arthritis

TOPADUR Pharma presents dual PDE5A inhibitors/soluble guanylate cyclase activators

Health Canada approves initiation of COVID-19 study of EB-05

New therapeutic target identified for emphysema in COPD

Syndrome with oculo-cerebral anomalies connected to PLXNA1 gene variants

Ilaris approved in U.S. for active Still's disease

FDA approves Cosentyx for active nonradiographic axial spondyloarthritis

FDA clears start of phase II trial of Metablok to prevent acute lung and kidney injury in COVID-19

Phase I results reported for BTK inhibitor TG-1701 in relapsed/refractory B-cell malignancies

Phase II study of APG-1387 for chronic hepatitis B doses first patient

FDA accepts IND for investigator-initiated trial of ATI-450 in hospitalized patients with COVID-19

Sinopharm's COVID-19 vaccine produces high-titer antibodies in phase I/II study

FDA allows Hookipa to study HB-202 with HB-201 for HPV-positive cancers

FDA clears initiation of phase II/III study of PTC-299 for COVID-19

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...